Ibrutinib-related atrial fibrillation: A single center Australian experience.

Saad EzadArshad A KhanHooria CheemaAsma AshrafDoan T M NgoAaron L SverdlovNicholas J Collins

Published in: Asia-Pacific journal of clinical oncology (2019)

In conclusion, this series noted a higher incidence of AF than previously reported. Oncologists and cardiologists need to be aware of the increased risk of AF in patients receiving ibrutinib.

Keyphrases

atrial fibrillation
chronic lymphocytic leukemia
oral anticoagulants
catheter ablation
left atrial
left atrial appendage
direct oral anticoagulants
heart failure
risk factors
percutaneous coronary intervention
venous thromboembolism
drug induced